Angeles Wealth Management LLC Buys 369 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Angeles Wealth Management LLC increased its stake in Eli Lilly and Company by 7.8%, acquiring an additional 369 shares and bringing its total holdings to 5,126 shares valued at approximately $4.23 million.
• Eli Lilly reported a quarterly EPS of $3.34, falling short of analysts' expectations, despite a 45.2% increase in revenue year-over-year.
• The company announced a quarterly dividend of $1.50 per share, yielding 0.74%, with an ex-dividend date of August 15.

Angeles Wealth Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,126 shares of the company's stock after buying an additional 369 shares during the period. Angeles Wealth Management LLC's holdings in Eli Lilly and Company were worth $4,234,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Garner Asset Management Corp increased its position in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after acquiring an additional 12 shares during the last quarter. Applied Finance Capital Management LLC grew its stake in Eli Lilly and Company by 1.4% in the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company's stock valued at $660,000 after purchasing an additional 12 shares during the period. Tobias Financial Advisors Inc. increased its position in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after purchasing an additional 12 shares during the last quarter. Redwood Investments LLC increased its position in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after purchasing an additional 12 shares during the last quarter. Finally, Hobbs Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.8%

Shares of NYSE LLY opened at $811.73 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average of $771.95 and a 200-day moving average of $800.41. The firm has a market capitalization of $769.31 billion, a price-to-earnings ratio of 66.05, a PEG ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.58 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Guggenheim raised their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. UBS Group lowered their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.